Aurinia Announces PTAB Has Terminated Inter Partes Review

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 25, 2024

Raptive and BOMESI Partner to Unlock Large-Scale Investment in Diverse-Owned Media • Attorneys File Sexual Assault Lawsuit Against Fort Worth Massage Envy • Introducing Home Planet Fund: A radically different approach to the climate crisis • More Preparation, Communication and Control: Hyatt Reveals Survey Findings on the Hotel Stay Needs of Neurodivergent Travelers • BABE BY BUCKED UP MAKES ITS OFFICIAL DEBUT IN MAJOR RETAILERS NATIONWIDE • ComEd Joins Bronzeville Community to Unveil New Public EV Chargers • UrbanGeekz Inks Groundbreaking Content Syndication Deal with Black-Owned Ridesharing App Moovn • AFFIRM FILMS AND PROVIDENT FILMS REVEAL THE OFFICIAL TRAILER FOR THE NEWEST KENDRICK BROTHERS' THEATRICAL RELEASE: 'THE FORGE' • Alterra Mountain Company Closes Acquisition of Mike Wiegele Helicopter Skiing in British Columbia Final • Reconciliation and Treaty Implementation in action: Tsawwassen First Nation adds lands to Tsawwassen jurisdiction • Vagaro Survey Highlights Neurodiversity in the Salon & Spa Industry • AHF Withdraws Bid to Purchase Skid Row Housing Trust Buildings • MLF Announces Launch of New Multi-Year Sponsorship and Licensing Partnership with REDCON1 • Ministers Vandal and Blair and MP McLeod highlight Budget 2024 investments to support post-secondary education in the North • August Health Unveils Inaugural Members of New Advisory Board • Ramp Metals Inc. (TSXV: RAMP) Opens the Market • Creating Opportunities: STEM Advantage Continues to Open Doors for STEM-Focused Scholars • Toyota Charges Up Investment and Jobs in U.S. Manufacturing • OpenGate Capital Completes Sale of SMAC • Wells Fargo Expands Down Payment Grant Program to Help Bridge Homeownership Gap

Aurinia Announces PTAB Has Terminated Inter Partes Review

VICTORIA, British Columbia , January 25 /Businesswire/ - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036.

About LUPKYNIS

LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death. It is one of the most serious and common complications of the autoimmune disease systemic lupus erythematosus (SLE). LUPKYNIS is in the United States (U.S.) and across the European Union (E.U).

About Lupus Nephritis

LN is a serious manifestation of SLE, a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the U.S. and about one-third of these people are diagnosed with lupus nephritis at the time of their SLE diagnosis. About 50 percent of all people with SLE may develop lupus nephritis. If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney. Black and Asian individuals with SLE are four times more likely to develop LN and individuals of Hispanic ancestry are approximately twice as likely to develop the disease when compared with Caucasian individuals. Black and Hispanic individuals with SLE also tend to develop LN earlier and have poorer outcomes when compared to Caucasian individuals.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS^® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.